加载中
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
收盘时
US$8.80
−US$0.13 · -1.46%
盘后
US$8.70
−US$0.10 · -1.14%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日内区间
当前US$8.80
52周区间
当前US$8.80
盘中时间采用ET。市场数据可能有所延迟。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日内区间
当前US$8.80
52周区间
当前US$8.80
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 200万 USD | — | — |
| 毛利 | — | — | 200万 USD | — | — |
| 研究与开发 | 3905.4万 USD | 3844.4万 USD | 1977.7万 USD | 2491.9万 USD | 1934万 USD |
| 销售、一般及管理费用 | 1783.5万 USD | 1601万 USD | 1296.3万 USD | 613.6万 USD | 437.9万 USD |
| 营业费用 | 5688.9万 USD | 5445.4万 USD | 3274万 USD | 3105.5万 USD | 2371.9万 USD |
| 利息收入 | 585.1万 USD | 888.7万 USD | 286万 USD | 55.3万 USD | 2.6万 USD |
| 折旧和摊销 | — | — | — | 13万 USD | — |
| 营业利润 | −5688.9万 USD | −5445.4万 USD | −3074万 USD | −3105.5万 USD | −2371.9万 USD |
| 净利润 | −5103.8万 USD | −4556.7万 USD | −2787.6万 USD | −3049.9万 USD | −2444.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.00
上涨空间 127.27%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1909.62万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1376.44万0.02%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1110.64万0.11%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF684.89万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB398.13万0.04%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO371.89万0.03%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO346.32万0.02%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS237.24万0.01%338.69亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
